Monoclonal antibody stro-4
AssigneeMesoblast, Inc.
InventorsStan Gronthos, Andrew Christopher William Zannettino
Life of this patent
Estimating the term…
Abstract
The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).
Claims15
1-20. (canceled)
An enriched population of multipotential cells obtained by a method of enriching a sample of cells for multipotential cells, the method comprising preparing a sample of cells from a tissue source and enriching for cells that express the HSP-90beta marker.
A method for identifying the presence of a multipotential cell in a cell sample, the method comprising identifying cells in the sample that express the HSP-90beta marker.
An HSP-90beta binding agent or antigen-binding fragment or antigen-binding derivative thereof selected from the group consisting of:
- (i) a STRO-4 monoclonal antibody;
- (ii) a chimeric antibody comprising heavy and light chain variable regions from STRO-4 and human heavy and light chain constant regions;
- and
- (iii) a humanized antibody comprising at least one complementarity determining region (CDR) from STRO-4 and human framework and constant region sequences.
A STRO-4 hybridoma cell line deposited under ATCC Accession Number PTA-9362.
An isolated antibody or antigen binding fragment thereof which binds to the same epitope on mesenchymal precursor cells (MPCs) as the STRO-4 antibody produced by the hybridoma cell line deposited under ATCC Accession Number PTA-9362.
Dependencies are inferred from the claim text.